Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial

BACKGROUND: Recurrent glioblastoma (GBM) has dismal outcomes and limited treatment options. Mebendazole (MBZ) has activity in glioma both in-vivo and in-vitro, and is well tolerated in combination with lomustine (CCNU) and temozolomide (TMZ). In this study, we sought to determine whether the additio...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Vijay M., Menon, Nandini, Chatterjee, Abhishek, Tonse, Raees, Choudhari, Amit, Mahajan, Abhishek, Puranik, Ameya D., Epari, Sridhar, Jadhav, Monica, Pathak, Shruti, Peelay, Zoya, Walavalkar, Rutuja, Muthuluri, Hemanth K., Ravi Krishna, Madala, Chandrasekharan, Arun, Pande, Nikhil, Gupta, Tejpal, Banavali, Shripad, Jalali, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156991/
https://www.ncbi.nlm.nih.gov/pubmed/35747192
http://dx.doi.org/10.1016/j.eclinm.2022.101449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156991/
https://www.ncbi.nlm.nih.gov/pubmed/35747192
http://dx.doi.org/10.1016/j.eclinm.2022.101449

Ejemplares similares